JS212 and JS111 for EGFR-mutated advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two experimental drugs, JS212 and JS111, as a first treatment for advanced lung cancer with a specific EGFR mutation. It aims to see if the combination can shrink tumors and help people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced lung cancer (that has spread or come back) with a specific EGFR mutation (exon 19 deletion or L858R).
- You have not had any cancer treatment for advanced disease before (though prior early-stage treatment more than 6 months ago is okay).
- You are healthy enough to be up and about (ECOG score 0 or 1).
- You do not have certain other lung cancer types, brain symptoms, or uncontrolled fluid buildup.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two new drugs (JS212 and JS111) for advanced non-squamous lung cancer that has an EGFR gene mutation and has progressed despite previous EGFR-targeted therapy. The combination may help control the cancer better than standard treatments.
This trial tests a new drug called JS212 combined with other treatments for people with advanced or spreading lung cancer. It aims to see if the combination can help shrink tumors or slow the disease.
This trial tests a new drug called JS207 for people with advanced non-small cell lung cancer (NSCLC) that has gotten worse after standard treatments like chemotherapy and immunotherapy. It aims to see if JS207 can help shrink tumors or slow the cancer's growth.
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a new drug called JS212 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can help shrink tumors.
This trial tests a new combination of drugs (JS212 plus another medicine) for people with advanced esophageal squamous cell carcinoma who have not had prior treatment. It aims to see if the combination is safe and effective.
Hear when a new NSCLC Harboring EGFR Mutations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.